HIV/AIDS – Medxy AI

Tailored Implementation of Systems Navigation and Psychosocial Counselling to Enhance HIV Care Engagement among People Who Inject Drugs in Viet Nam: Evidence from a Cluster-Randomised Trial

By MedXY 11/30/2025

A tailored approach to implementing systems navigation and psychosocial counselling significantly improved intervention fidelity and viral suppression among people with HIV who inject drugs in Viet Nam, compared to a standard strategy, highlighting the value of context-sensitive interventions.

HIV/AIDS Infectious Diseases news

High Viral Suppression with TLD in PEPFAR Programs — But Resistance and Adherence Signals Require Targeted Action

By MedXY 11/29/2025

A multinational prospective cohort found high viral suppression after switching or initiating tenofovir–lamivudine–dolutegravir (TLD), but emergent dolutegravir-resistance was detected in a small subgroup with prior virological failure and poor adherence, highlighting the need for monitoring and adherence support.

HIV/AIDS Infectious Diseases news

Dolutegravir + Lamivudine Is Non‑Inferior to Bictegravir/FTC/TAF for Maintenance Therapy at 48 Weeks: PASO‑DOBLE Randomised Trial

By MedXY 11/13/2025

In PASO‑DOBLE, switching virologically suppressed adults to dolutegravir/lamivudine maintained viral suppression at 48 weeks and was non‑inferior to switching to bictegravir/emtricitabine/tenofovir alafenamide, supporting shared decision‑making for maintenance regimen selection.

Clinical Updates HIV/AIDS news

Early Clinical Evaluation of Novel Broadly Neutralising Monoclonal Antibodies for HIV-1: Safety, Pharmacokinetics, and Neutralisation Profiles of N6LS, PGDM1400LS, and PGT121.414.LS

By MedXY 11/13/2025

This review summarizes early-phase clinical trials assessing the safety, pharmacokinetics, and neutralisation activity of three innovative broadly neutralising monoclonal antibodies—N6LS, PGDM1400LS, and PGT121.414.LS—for HIV-1 prevention and therapy.

HIV/AIDS news

Infant Safety After In-Utero Exposure to Dapivirine Ring or Oral PrEP: 12‑Month Findings from MTN‑042/DELIVER

By MedXY 11/12/2025

In a randomized phase 3b trial of pregnant women using the dapivirine vaginal ring or daily oral TDF/FTC for HIV prevention, 12‑month infant follow‑up showed no product‑related serious or grade 3+ adverse events and no HIV transmissions, supporting PrEP use in pregnancy.

HIV/AIDS news Pediatrics

Once‑Daily Dolutegravir/Lamivudine Fixed‑Dose Tablets Achieve Robust Pediatric Exposures and Reassuring Safety in the D3/PENTA 21 PK Sub‑Study

By MedXY 11/12/2025

A nested PK and safety sub‑study of D3/PENTA 21 shows once‑daily DTG/3TC dispersible and film‑coated fixed‑dose tablets deliver adequate drug exposures across WHO weight bands in children 2–<15 years, with no drug‑related discontinuations and comparable PK to historical pediatric data.

HIV/AIDS news Pediatrics

Dolutegravir from Birth: PETITE‑DTG Shows Safe, Targeted Neonatal Dosing for Term Newborns

By MedXY 11/12/2025

First randomized neonatal PK/safety data show 5 mg dolutegravir (dispersible tablet or oral film) every 48 hours for two weeks, then daily to day 28, achieves target troughs with acceptable safety in term infants born to mothers on dolutegravir-based ART.

HIV/AIDS Infectious Diseases news

A 21‑Valent Adult Pneumococcal Conjugate Vaccine (V116) Is Immunogenic and Well Tolerated in People Living with HIV: Results from STRIDE‑7

By MedXY 11/12/2025

In STRIDE‑7, the adult‑specific 21‑valent conjugate vaccine V116 produced robust opsonophagocytic responses across all 21 serotypes and had a favorable tolerability profile in adults living with HIV, supporting broader serotype coverage compared with currently licensed vaccines.

HIV/AIDS news Pediatrics

Very Early Neonatal ART Enables ART‑Free HIV‑1 Remission in Some Children: Clinical Insights from IMPAACT P1115

By MedXY 11/12/2025

IMPAACT P1115 shows that initiating combination ART within 48 hours of birth can enable sustained ART‑free HIV‑1 remission for 48+ weeks in a subset of children with in‑utero infection, but careful selection, close monitoring and standardized biomarkers are essential.

HIV/AIDS news OB/GYN & Women's Health

Dapivirine Ring and Oral PrEP in Pregnancy: MTN-042/DELIVER Shows Infant Safety Through 12 Months

By MedXY 11/12/2025

A randomized phase 3b trial found no infant safety signals attributable to in-utero exposure to the dapivirine vaginal ring or oral tenofovir–emtricitabine PrEP over 12 months of follow-up, supporting use of both options for HIV prevention in pregnancy.

HIV/AIDS news Psychiatry

Can Modafinil Break the Sleep–Mood Cycle in People Living with HIV?

By MedXY 11/12/2025

Sleep disorders and depression are common in people living with HIV. Modafinil may improve daytime sleepiness, fatigue and cognition—especially for OSA-related EDS or augmentation in depression—but HIV-specific RCT data and ART interaction studies are limited.

HIV/AIDS news Psychiatry

Breaking the Cycle: How Modafinil Offers Hope for Sleep and Mood Disorders in HIV Patients

By MedXY 11/12/2025

Sleep disturbances and mood disorders profoundly affect people living with HIV. Modafinil emerges as a promising therapy addressing daytime sleepiness, depression, and cognitive challenges, improving quality of life.

Diabetes & Endocrinology HIV/AIDS Internal Medicine Specialties

Nucleoside Reverse Transcriptase Inhibitors: A Novel Therapeutic Avenue Against Inflammaging and Age-Related Diseases

By MedXY 10/22/2025

NRTIs, traditionally used in HIV and HBV treatment, demonstrate promising anti-inflammatory effects that may reduce the incidence of age-related diseases by inhibiting inflammaging processes associated with endogenous retroelements.

HIV/AIDS Infectious Diseases news

Accelerated Epigenetic Aging in HIV: Insights from a Systematic Review

By MedXY 10/22/2025

Systematic review evidence supports accelerated epigenetic aging in people living with HIV compared to uninfected individuals, highlighting the need for further research considering antiretroviral therapy and confounding factors.

HIV/AIDS Infectious Diseases Specialties

Long-Term Health Risks in HIV Patients with Immune Non-Response Despite Antiretroviral Therapy

By MedXY 10/22/2025

Immune non-response despite ART in people with HIV significantly increases risk of both AIDS-defining and non-AIDS-defining comorbidities, underscoring the need for enhanced risk assessment beyond CD4+ T-cell counts.

Dermatology HIV/AIDS Specialties

Evolving Dermatologic Landscape in HIV: Prevalence, Incidence, and Risk Factors in the Modern ART Era from the DC Cohort

By MedXY 10/22/2025

Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.

HIV/AIDS Infectious Diseases Specialties

Understanding Motivations and Barriers in Donation-Based HIV/STI Interventions: Insights from a Systematic Review

By MedXY 10/22/2025

This review synthesizes motivations, facilitators, and barriers of donation-based interventions in HIV/STI research, revealing key factors that enhance access to services through prosocial behaviors in diverse global settings.

HIV/AIDS Infectious Diseases Public Health Specialties

HIV Among Older Adults in Sub-Saharan Africa: Epidemiology, Risks, and Treatment Insights from the AWI-Gen Longitudinal Study

By MedXY 10/20/2025

This multicentre longitudinal cohort study reveals significant HIV prevalence and incidence among adults aged 40 and older in sub-Saharan Africa, highlighting age, gender, education, and rural residency as critical factors influencing HIV risk and treatment outcomes.

Cardiology HIV/AIDS news Specialties

Early HIV Treatment and Cardiovascular Health: Insights from the START Study

By MedXY 10/09/2025

Early ART initiation in HIV-positive adults with high CD4+ counts shows no overall cardiovascular benefit, but reduced CVD events in women suggest potential sex-specific effects needing further study.

Clinical Updates HIV/AIDS news Respiratory

Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial

By MedXY 09/21/2025

A multicentre randomized trial evaluated adjunctive corticosteroids in HIV-negative severe Pneumocystis jirovecii pneumonia, showing a non-significant reduction in 28-day mortality and no safety concerns, and calls for further targeted research.